术前短期给予来曲唑对（激素阳性）乳腺癌患者Ki-67的有效降低作用
Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer.
作者信息
Eslami Bita, Alipour Sadaf, Golfam Farzaneh, Jahabnin Behnaz, Omranipour Ramesh
机构信息
Breast Diseases Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Department of Surgery, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran.
出版信息
Iran J Pathol. 2024 Winter;19(1):103-106. doi: 10.30699/IJP.2023.2002772.3118. Epub 2023 Dec 29.
BACKGROUND & OBJECTIVE: Antigen Ki-67 (histone-based nuclear protein) is a static marker of tumor cell proliferation and growth and is commonly measured to indicate the effect of treatment in breast cancer patients. This single-arm trial study aimed to evaluate the effect of short-term endocrine therapy (letrozole) on Ki-67 levels in menopausal women with early hormone-positive breast cancer who were referred to two university hospitals.
METHODS
Patients with a pre-treatment Ki67 of 5% or less were excluded from the study. Participants (n=25) received oral letrozole (2.5 mg daily) seven days before surgery. Ki-67% on both biopsies and the surgical specimens were measured and compared.
RESULTS AND CONCLUSION
The mean age of patients was 62±9.4 (48-83 years). Our result indicated that pre-surgery consumption of letrozole for hormone-positive breast cancer can significantly decrease the of Ki-67 labeling index (23.24±9.74 vs. 16.92±9.55, =0.001 by paired t-test), with no drug-related adverse events.
背景与目的
抗原Ki-67（基于组蛋白的核蛋白）是肿瘤细胞增殖和生长的静态标志物，常用于评估乳腺癌患者的治疗效果。这项单臂试验研究旨在评估短期内分泌治疗（来曲唑）对两家大学医院收治的绝经后早期激素阳性乳腺癌女性患者Ki-67水平的影响。
方法
预处理时Ki67为5%或更低的患者被排除在研究之外。参与者（n = 25）在手术前7天接受口服来曲唑（每日2.5毫克）。测量并比较活检组织和手术标本的Ki-67%。
结果与结论
患者的平均年龄为62±9.4岁（48 - 83岁）。我们的结果表明，激素阳性乳腺癌患者术前服用来曲唑可显著降低Ki-67标记指数（配对t检验，23.24±9.74对16.92±9.55，P = 0.001），且无药物相关不良事件。
Zotero 插件